A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

BACKGROUND. The phase II YO28252 study (NCT01590719) examined first-line onartuzumab plus mFOLFOX6 in patients with metastatic, human epidermal growth factor receptor 2-negative adenocarcinoma of the stomach or gastroesophageal junction. MET immunohistochemistry expression as a biomarker of onartuzu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: Shah, Manish A., Cho, Jae-Yong, Tan, Iain B., Tebbutt, Niall C., Yen, Chia-Jui, Kang, Alice, Shames, David S., Bu, Lilian, Kang, Yoon-Koo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AlphaMed Press 2016
Konular:
Gastrointestinal Cancer
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5016069/
https://ncbi.nlm.nih.gov/pubmed/27401892
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0038
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller